GBP exports vaccines to more than 14 countries around the world, including Australia, Taiwan and South Korea.
Company Profile
Global Biotech Product Company Limited, GBP (previously was Government Pharmaceutical Organization- Merieux Biological Product Company Limited) has been the historic supplier for the Thai Public market since 2002. This Joint-Venture between Substipharm Biologics, Government Pharmaceutical Organization (State enterprise) and Siam Bioscience was established in 1997 and is majority owned by Thai entities.
Strategically located, at 1 hour 15min from Bangkok international airport, GBP can easily take advantage of its location in Thailand to access to other markets from ASEAN Economic Community, using its supply chain capabilities for importation and exportation.
THE ORIGINS OF Global Biotech Products(GBP)
Get to know GBP
Beginning of Growth
1997: Established joint venture company named “Government Pharmaceutical Organization- Meriéux Biological Products (GPO-MBP)”, There were 3 shareholders: Government Pharmaceutical Organization, Bureau Crown Property, and Pasteur Meriéux Connaught
2000: Start construction of manufacturing site located at Gateway City Industrial Estate, Chachoengsao
Technical Expertise
2002: First two Vaccines: Rabies Vaccine and Hepatitis B vaccine were licensed and commercialized for Thai National Immunization Program
2002-2008: Manufactured Vaccines were supplied Thai National Immunization Program under privileged including: Hepatitis B vaccine, Rabies Vaccine, MMR vaccine, Trivalent Influenza vaccine, and DTP-Hep B vaccine. They were under Technology Transferred by Sanofi Pasteur
2006: Manufactured and Licensed Measles Vaccine in Thailand
2007: Develop Live attenuated Live attenuated Japanese Encephalitis Vaccine, recombinant from research to industrial scale
2010: Live attenuated Japanese Encephalitis Vaccine, recombinant was licensed in Australia
2010: Granted WHO Prequalification on Live attenuated Measles Vaccine
2014: Granted WHO Prequalification on Live attenuated Japanese Encephalitis Vaccine, recombinant
2022: 1st December 2022 Substipharm Biologics acquired IMOJEV and Shared of GPO-MBP from Sanofi Pasteur. The company name was changed to Global Biotech Products (GBP) until now
GBP Manage Technology
Strongly known for the technical expertise of its people and for the high quality and compliance level, GBP is the unique manufacturer prequalified by WHO and TGA Australian (Health Agency) in Southeast Asian countries. For these reasons the site was chosen to register (country of origin), produce and distribute the Japanese Encephalitis live attenuated recombinant vaccine in the entire region including Australia.
Highly autonomous, GBP demonstrated its ability to manage technology transferred and launch products (11 launches in 10 years) and high level of flexibility of product presentations (1 Dose, 2 Doses, 4 Doses, 10 Doses).
Moving Together with Trust !
We are one of the largest toll and contract manufacturer in Southeast Asia for branded pharmaceutical and healthcare products.
24,000 m²
land at the Gateway City
Industrial Estate in Thailand
125 km
East of Bangkok
6
Buildings on site
8,000 m²
Constructed building surface
Serving
GBP has continuously shown its ability to produce vaccines to prevent various diseases since 2000. Currently, it sells vaccines to prevent cervical cancer and Japanese Encephalitis according to the national immunization plan and export of Japanese Encephalitis sold in more than 14 countries around the world, such as Australia, Taiwan and South Korea.
GBP’s 20+ years of continuous and consistent Production capabilities
Production site premises
The GBP operated a high-quality facility strategically located in the heart of Thailand
